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Case Study
Introduction
Ms P presented with apsychotic visual
hallucinations in the presence of de-
creased visual acuity. She was an 83-
year-old female with no prior psychiatric
complaints. Medically she suffered from
Paget’s disease, gastritis, osteoarthritis,
dyslipidaemia and bilateral macular de-
generation. This combination is known
as Charles Bonnet Syndrome, after a
Swiss philosopher who described it in
1796. The term hallucination is said to
come from the Latin word alucinari,
meaning “to wander in the mind”, and
was introduced by Esquirol in 1837. It
is defined as sensory perception that
has the compelling sense of reality of
a true perception without a correspond-
ing external stimulus to the correspond-
ing sensory organ.1 Charles Bonnet
described Charles Bonnet Syndrome
in his grandfather - Charles Lullin.2
Lullin underwent a bilateral cataract
extraction at the age of 89 and devel-
oped very clear visual hallucinations
of buildings that were not present. He
had no cognitive impairment and was
fully aware of the unreality of his ex-
periences. Visual acuity disturbance
is a frequent complaint of patients in
general practice.
Presentation
Ms P, an 83 year old female was referred
by her GP to me for evaluation. Her 59-
year-old eldest daughter accompanied
her. She had consulted an ophthalmolo-
gist in March 2003 due to visual fallout.
He diagnosed bilateral macular degen-
eration. Ms P’s main complaint was visual
hallucinations. She would see the faces
of her deceased mother, father, and
brother in front of her eyes. She also
displayed metamorphosia: a visual illu-
sion where she would see people’s faces
(including her own) changing shapes
and sizes, for example, everyone around
her would seem to develop a full beard.
These symptoms were ego-dystonic and
disturbing. They were unwanted and did
not feel part of her imagination, but repre-
sented reality. She was, for obvious
reasons, concerned about them. The
symptoms had persisted for a few
months but had no specific onset. Her
GP also treated her for depression, with
good effect, and she was totally euthymic
at the time of the interview. On special
testing she scored 7 on the Hamilton
Depression Rating Scale (21 questions),
which indicated the absence of depres-
sion. Her Folstein Mini Mental Score was
27/27, which is perfectly normal (three
questions were disregarded due to her
poor vision). Needham and Taylor in the
USA and Teunisse in the Netherlands
explored Charles Bonnet Syndrome. The
latter described the following “diagnostic
criteria”:3
1. Presence of complex visual halluci-
nations
2. Full retention of insight into the unreal
nature of the hal lucinat ions
3. Absence of hallucinations in other
sensory modalities
4. Absence of delusions
The incidence of the disorder ranges
between 5.1 (1 in 20) to 14.4% (1 in 10)
in patients with visual field pathology.
According to Teunisse, some patients
do not find the hallucinations disturbing
(13 % are amused by it), but 18% do
find them disturbing, while 10% find
them extremely discomforting, as did
Ms. P.3  Of Teunisse’s group:
• 65% of patients hallucinated weekly
or monthly and 27% daily, as in Ms
P’s case
• 80% of hallucinations involved peo-
ple, as in this case, while 38% in-
volved animals, 25% involved plants
or  trees, and 15% involved buildings
or scenes, as in Lullin’s case
• 63% of hallucinations were in colour,
47% involved movement and 45%
were seen with more clarity than
“real” objects
• 53% of hallucinations lasted 1 - 60
minutes and 13% lasted less than 5
seconds
• 67% of patients experienced the
hallucinations with open eyes. 3
Prior Psychiatr ic History
In Ms P’s case, no prior personal or
family history of any mental disorders
was present. A differential diagnosis for
Charles Bonnet Syndrome includes: 2
1. Psychological events:  Mourning
and stress, Sensory deprivation,
Sleep deprivation, Acquired deaf-
ness, Phantom limb experiences,
Flashback phenomena
2. Due to psycho-mimetic drugs:
LSD, PCP, Peyote, Psilocybin, Can-
nabis
3. Neurological aetiology: Epilep-
sy, Migraine, Vertiginous, Hypnogog-
ic and hypnopompic
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4. Medical aetiology: Multiple scle-
rosis, Serous otitis media, Intra-otic
foreign bodies
5. Pseudo-hallucinations: Radio
reception via shrapnel wound in cra-
nial bone of left parieto-occipital re-
gion, resonating to a frequency of
560 AM, Virtual reality exposure, Ma-
lingering
Past Medical History:
Ms P suffered from bilateral macular
degeneration with scotomae, Paget’s
disease with osteoporosis, dyslipidae-
mia, gastritis and osteoarthritis.
Current Medication:
Rabeprazole 10 mg daily; Alendronate
70 mg weekly; Calcium supplement I
bid; Conjugated oestrogen 1,25 mg dai-
ly; Meloxicam 7,5 mg daily; Amitriptyline
25 mg nocte; Citalopram 20 mg daily;
and Atorvastatin 10 mg daily
Substance use:
Neither Ms P nor her daughter noted
any problems due to present or past
substance misuse.
Biography:
Ms P is the youngest of five children.
She had an unremarkable childhood
with no specific problems. Her highest
academic qualification was Standard 9
(Grade 11) and she spent her life, after
the birth of her children, as a mother
and homemaker. She supplemented the
family income by making dresses in her
spare time and this developed into a
small business enterprise. She was
married three times. She divorced her
first husband after three months of mar-
riage due to his alcohol abuse. Both her
second and third husband passed away
and she has been a widow since 1995.
She currently stays in an old age home
and lives off her pension and invest-
ments.
Significant risk factors for the devel-
opment of Charles Bonnet Syndrome,
according to Teunisse, are:3
1. Loss of energy
2. A large number of co-morbid somatic
disorders (as are present in this case)
3. Beta blocking agents




It is also necessary to screen for delirium,
dementia and vascular brain disease
(usually in the occipito-parietal or occip-
ito-temporal areas).
Mental Status
Ms P was a well-groomed, courteous,
and friendly elderly lady. She walked
unaided and accompanied by her
daughter, with whom she seems to have
a comfortable relationship. She spoke
freely and easily and we developed rapid
rapport. She seemed calm and at ease.
Ms P had a full affect, which responded
appropriately. Her language skills were
intact, but she displayed obvious visual
problems. She was fully awake and con-
scious and showed no signs of either a
delirium or a dementia. No cognitive
symptoms were elicited. Except for the
complaint of visual hallucinations, she
was apsychotic. Her thought processes
were normal in rate, form, and content.
No mood or anxiety symptoms were
elicited. The patient and her daughter
were counselled about her condition
and reassured about the absence of
major psychiatric disorders.
Investigations
CT brain scan, with special emphasis
on the occipito-temporal and occipito-
parietal areas, revealed generalised
cerebral atrophy, in keeping with her
age, but no specific pathology was not-
ed. An electroencephalogram (EEG),
with emphasis on the temporal and oc-
cipital areas and examined by two ex-
perienced neurophysiologists, was within
normal limits.
Management
Treatment with Risperidone 0.5 mg nocte
for two weeks was initiated as a thera-
peutic trial. Ms. P experienced side ef-
fects due to the Risperidone, mainly
dizziness and fatigue. She also devel-
oped orthostatic hypotension, as well
as signs of congestive heart failure; the
Risperidone was subsequently down-
titrated and stopped.  Quetiapine, at a
dose of 25 mg nocte, was initiated for a
two-week period, to which she respond-
ed very favourably, with only minor com-
plaints of somnolence. Ms P declined
up-titration of this dose, despite its sug-
gestion. This low dose of antipsychotic
medication might have been effective
via an anxiolytic mechanism rather than
an antipsychotic action. The techniques
developed by Teunisse and his group
for dealing with the hallucinations are:3
1. Closing the eyes
2. Opening the eyes
3. Blinking the eyes
4. Moving the eyes rapidly
5. Looking or walking away from the
hallucinations
6. Approaching the hallucinations
7. Visual fixation on the hallucinations
8. Distraction techniques
9. Hit t ing at the hal lucinat ions
10. Shouting at the hallucinations.
His protocol calls for psycho-education,
an improvement of physical health, med-
ication replacement and a decrease of
social isolation.According to Rovner,
treatment should consist of education
and reassurance.4 Antipsychotic and
anti-epileptic medications may be of
value. Some of these hallucinations dis-
appear spontaneously within 12 to 18
months. Increased lighting at home and
decreased social isolation are recom-
mended. Both the patient and clinician
were satisfied with the outcome of this
interesting case after prolonged treat-
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